First meeting of the Modelling and Simulation Working Group
NewsCorporate
The European Medicines Agency's Modelling and Simulation Working Group (MSWG) has met today for the first time.
The Agency has a number of working parties and related groups, which can be consulted by the Agency's scientific committees on scientific issues relating to their particular field of expertise.
The Agency is working for a greater integration of modelling and simulation in the development and regulatory assessment of medicines. It considers the methodology to be a powerful tool that could provide an opportunity to improve the efficiency of medicine development, and also could facilitate the regulatory assessment of medicines.
The Agency's MSWG will meet monthly and provide support to the Agency's scientific committees and working parties, including the Committee for Medicinal Products for Human Use (CHMP), the Paediatric Committee (PDCO) and the Scientific Advice Working Party (SAWP), on product-related issues but also in more general methodological discussions and qualification procedures regarding modelling and simulation.
Objectives of the MSWG
The objectives of the Group are:
The MSWG will elect its chair and adopt a mandate and work plan over the next few meetings.